Thus, our aim is to use a novel perturbation gene expression signature approach to identify subgroups of ER+ patients who respond less well to endocrine therapy, but who may benefit from treatments targeting cancer genes that are active in these tumor subgroups. Here, ESR1 is linked to cancer.